Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition(s):Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell LymphomaLast Updated:December 7, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell LymphomaLast Updated:December 7, 2023Not yet recruiting
Condition(s):Peripheral T Cell LymphomaLast Updated:October 19, 2023Not yet recruiting
Condition(s):Peripheral T-Cell LymphomaLast Updated:December 13, 2023Recruiting
Condition(s):Peripheral T-cell LymphomaLast Updated:October 5, 2016Completed
Condition(s):Peripheral T Cell LymphomaLast Updated:September 28, 2023Recruiting
Condition(s):Peripheral T Cell LymphomaLast Updated:November 18, 2023Recruiting
Condition(s):Peripheral T-cell LymphomaLast Updated:October 14, 2019Completed
Condition(s):Peripheral T-cell LymphomaLast Updated:October 26, 2017Unknown status
Condition(s):Peripheral T-cell LymphomaLast Updated:May 11, 2021Recruiting
Condition(s):Lymphoma, T-Cell, PeripheralLast Updated:September 1, 2021Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.